Press release
Nicox: Half-year report on the NICOX liquidity contract
January 6, 2022 – release at 7:30 am CET
Sophia Antipolis, France

Under the liquidity contract concluded between Nicox SA (Euronext Paris: FR0013018124, COX) and Kepler Cheuvreux, the following resources appeared in the liquidity account at December 31:st 2021:

– 211,967 shares
– € 146,491.49

– Number of buy side executions over the semester: 786
– Number of executions on the seller’s side over the semester: 728
– Volume traded on the buy side over the half-year: 387,737 shares for € 1,278,136.61
– Volume traded on the seller’s side over the semester: 394,689 shares for € 1,304,467.12

As a reminder :

• the following resources appeared on the last half-year closing on June 30, 2021 on the liquidity account:

– 218,919 shares
– € 128,032.29

– Number of executions on the purchase side over the semester: 1,594
– Number of executions on the seller’s side over the semester: 1,298
– Volume traded on the buy side over the half-year: 978,682 shares for € 4,245,529.01
– Volume traded on the seller’s side over the semester: 906,908 shares for € 3,977,929.37

• the following resources appeared in the liquidity account at the start of the activity:

– 0 sharing
– € 500,000.00

This report is executed in accordance with AMF decision N ° 2021-01 of the month of June.
22sd 2021 renewing the implementation of equity liquidity contracts as an accepted market practice.

About Nicox
Nicox SA is an international ophthalmology company that develops innovative solutions to help maintain vision and improve eye health. Nicox’s flagship clinical development program is NCX 470, a novel nitric oxide donor prostaglandin analog for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis. Nicox generates income from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb and ZERVIATE® in allergic conjunctivitis, licensed in several geographies, including Eyevance Pharmaceuticals, LLC, in the United States and Ocumension Therapeutics in China and the majority of Southeast Asian markets.

Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indices.

For more information about Nicox, its products or its pipeline, please visit: www.nicox.com.

Analyst coverage

Bryan, Garnier & Co Dylan van Haaften Paris, France
Edison Investment Research Pooya Hemami London, United Kingdom
HC Wainwright & Co Yi Chen New York, United States
Kepler Cheuvreux Damien Choplain Paris, France

The opinions expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. In addition, the information in their reports may not be correct or up to date. Nicox disclaims any obligation to correct or update information contained in analyst reports.
Contacts
Nicox
Gavin Spencer
Executive Vice-President, Chief Business Officer
& Head of business development
T +33 (0) 4 97 24 53 00
[email protected]
Investors and media
United States and Europe
LifeSci Advisors, LLC
Sandya von der Weid
T +41 78 680 05 38
[email protected]
Media
France
LifeSci Advisors, LLC
Sophie Baumont
T +33 (0) 6 27 74 74 49
[email protected]
Forward-looking statements
The information contained in this document is subject to change without notice. This information includes forward-looking statements. These forward-looking statements are not guarantees of future performance. These statements are based on the current expectations or beliefs of the management of Nicox SA and are subject to a number of factors and uncertainties which could cause actual results to differ materially from those described in forward-looking statements. Nicox SA and its affiliates, directors, officers, employees, advisers or agents, do not undertake and have no obligation to provide updates or revise forward-looking statements.

The risk factors likely to have a significant effect on Nicox’s activity are presented in the 3e chapter of the ‘Universal registration document, annual financial report and management report 2020‘deposited with the French Financial Markets Authority (AMF) on March 1, 2021 and on 2sd chapter of the amendment to “Universal Registration Document, annual financial report and management report 2020»Filed with the AMF on December 9, 2021, which are available on the Nicox website (www.nicox.com).

Nicox SA
Drakkar 2
Building D, 2405 route des Dolines
CS 10313, Sophia Antipolis
06560 Valbonne, France
T +33 (0) 4 97 24 53 00
F +33 (0) 4 97 24 53 99
  • FR_2021 half-year report_Nicox PR_20220106_F1